•Complement Therapeutics begins patient dosing in GA gene therapy trial •TED may cause reduced stromal corneal thickness•Study urges alternative tracking for wet AMD poor responders•Positive 24-month data supports the Elios System for glaucoma treatment•VirtuaLens launches monovision simulation for VR IOL simulator •Complement Therapeutics begins patient dosing in GA gene therapy trial •TED may cause reduced stromal corneal thickness•Study urges alternative tracking for wet AMD poor responders•Positive 24-month data supports the Elios System for glaucoma treatment•VirtuaLens launches monovision simulation for VR IOL simulator
HEADLINES
FEATURED
Tyrosine kinase inhibitors may act as an additional risk factor for RVO in patients with existing vascular comorbidities.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
